Watson Will Pursue “Balanced” Generic Portfolio, CEO Bisaro Says
Executive Summary
Watson Pharmaceuticals will aim for a "balanced" generic drug portfolio by moving beyond "commodity" products to include more of those that are especially difficult to formulate or manufacture, new President and CEO Paul Bisaro said during the firm's third quarter earnings call Nov. 6
You may also be interested in...
Watson nets Barr exec as CEO
Barr President and Chief Operating Officer Paul Bisaro will succeed longtime Watson CEO and founder Allen Chao, effective Sept. 4. Bisaro has worked for Barr since 1992, and became president and COO in 2006. Among his more recent accomplishments is helping guide the acquisition of Pliva, which closed in October 2006 (1"The Pink Sheet" Oct. 30, 2006, In Brief). Barr CEO Bruce Downey will now take over Bisaro's responsibilities on an interim basis, according to Barr, which maintains there is no "urgency" in naming a replacement. Barr also will need to re-evaluate its succession plan, as Bisaro was widely viewed as the choice to take over when Downey retires...
Watson Acquisition Of Andrx Includes Drug Delivery Technology, ANDA Hold
Watson's acquisition of Andrx will provide the company with 15 drug delivery technologies, including delayed and sustained-release formulations
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.